Integrated DNA Technologies (IDT) and Aldevron, both subsidiaries of Danaher (NYSE: DHR), have jointly launched research grade S.p. Cas9 mRNA in wild type and SpyFi™ high-fidelity formats for use in CRISPR-based genome editing workflows, according to a press release.

The co-developed product combines IDT's CRISPR engineering expertise with Aldevron's mRNA manufacturing capabilities. The offering is designed to support on-target editing across multiple cell types, including T cells, iPSCs, and immortalized cells. The SpyFi high-fidelity format is intended to reduce off-target editing activity.

The mRNA constructs are compatible with delivery via electroporation, cationic lipids, and lipid nanoparticles. The Cas9 mRNA is enzymatically capped, which the companies say reduces reliance on certain proprietary capping technologies and associated licensing requirements.

The products are available in research grade formats, with the companies stating a path exists to scaled current good manufacturing practice (CGMP) versions as programs advance. IDT and Aldevron describe this launch as the first in a planned series of co-developed offerings, with base and prime editor products expected later this year.

"By connecting IDT's CRISPR protein engineering expertise with Aldevron's mRNA manufacturing capabilities, scientists will now have access to an optimized Cas9 mRNA offering designed to support efficient editing, reduced off-target risk, and greater continuity as their programs advance," said Christopher Vakulskas, senior director of applied science and molecular design at IDT.

IDT is headquartered in Coralville, Iowa, and Aldevron is based in Fargo, North Dakota. Both companies are designated as research use only product providers under this offering, meaning the products are not intended for diagnostic or therapeutic procedures in their current form.